TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges—particularly with regard to valve durability—need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines.
CITATION STYLE
Voigtländer, L., & Seiffert, M. (2018, July 12). Expanding TAVI to Low and Intermediate Risk Patients. Frontiers in Cardiovascular Medicine. Frontiers Media S.A. https://doi.org/10.3389/fcvm.2018.00092
Mendeley helps you to discover research relevant for your work.